Faculty profile

Stefano Comai

Back to faculty

Adjunct ProfessorDepartment of PsychiatryMcGill University

Stefano Comai

Adjunct Professor

Department of Psychiatry

Faculty of Medicine and Health Sciences

McGill University

Montreal, Quebec, Canada

Supervision signals

Adjunct, part-time and visiting faculty usually co-supervise alongside a core faculty member.
65 publications in the last five years, latest in 2026.
Senior (last) author on 17 recent papers, a sign of leading a research group.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

103

Publications

3,449

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their McGill University profile.

Latest papers

Neurophysiological and neuropharmacological effects of melatonin MT2 receptors activation in MK-801-induced schizophrenia-like dysfunctions.
Biochemical pharmacology · 2026 · senior author
Cannabidiol (CBD) modulates the serotonin-kynurenine metabolic balance in the brain of morphine-tolerant neuropathic rats.
Pharmacological reports : PR · 2026 · senior author
Sex-sensitive serotonergic signaling in psychedelic pharmacology.
Trends in pharmacological sciences · 2026 · senior author

All 103 publications

Latest funding

Lysergic acid diethylamide (LSD) and social behavior. A translational study.
CIHR · 2020 · Co-investigator
$784,126
Novel First-In-Class Melatonin MT2 Receptor Agonist for Neuropathic Pain: Investigational New Drug (IND) – Enabling Studies
BRAIN · 2019 · Co-investigator
$1,600,000

All 2 grants and awards

103 publications.

Neurophysiological and neuropharmacological effects of melatonin MT2 receptors activation in MK-801-induced schizophrenia-like dysfunctions.

Barzon B, Marchiotto F, Nasini S, Casile A, Peluso S, Cifani C, Pitsikas N, Gobbi G, Cambiaghi M, Comai S

Biochemical pharmacology20262 citationsSenior authorOpen Access

DOI: 10.1016/j.bcp.2026.117725 PMID: 41571206

Cannabidiol (CBD) modulates the serotonin-kynurenine metabolic balance in the brain of morphine-tolerant neuropathic rats.

Nasini S, Pearl-Dowler L, Lopez-Canul M, Posa L, Bertazzo A, Gobbi G, Comai S

Pharmacological reports : PR2026Senior authorOpen Access

DOI: 10.1007/s43440-026-00850-w PMID: 41874946

Sex-sensitive serotonergic signaling in psychedelic pharmacology.

Nasini S, Barzon B, Casile A, Richardson B, Gobbi G, Comai S

Trends in pharmacological sciences2026Senior authorOpen Access

DOI: 10.1016/j.tips.2026.07.006 PMID: 42575820

Up-Regulation of Anthranilic Acid Formation and Pro-Cognitive Effect of Indoleamine 2,3-Dioxygenase Inhibition.

Oxenkrug G, Comai S

International journal of tryptophan research : IJTR2026Senior author

DOI: 10.1177/11786469261472317 PMID: 42571168

Melatonin system integrity shapes gut-brain interaction in schizophrenia-derived microbiota transplant phenotype in mice.

Barzon B, Shkodra A, D'Incalci M, Sapienza J, Paribello P, Nasini S, Dall'Acqua S, Bertazzo A, Pitsikas N, De Gregorio D, Valtorta F, Manchia M, Squassina A, Fadda P, Cavallaro R, Pisanu C, Bosia M, Comai S

Life sciences2026Senior author

DOI: 10.1016/j.lfs.2026.124633 PMID: 42580395

Mutations in the three synapsin genes lead to profound social deficits and cortical dysfunctions.

Nicosia N, Monzani E, Regoni M, Comai S, Benfenati F, Valtorta F, De Gregorio D

Progress in neuro-psychopharmacology & biological psychiatry2026

DOI: 10.1016/j.pnpbp.2026.111810 PMID: 42349827

Pharmacokinetics and safety of a modified-release psilocybin formulation: A SAD Phase I trial in normal-weight and overweight/obese participants.

Signor A, Comai S, Pasut G, Folli F, Gentilucci M, Gharavi N, Raitsin S, Van Nguyen T, Pappagallo M, Mattarei A, Manfredi PL, De Martin S

British journal of clinical pharmacology2026

DOI: 10.1002/bcp.70839 PMID: 42767271

Central and peripheral monoamine changes in a rat model of Gaming Disorder.

Casile A, Bonaldo B, Bettarelli M, Papadopoulos P, Micioni Di Bonaventura MV, Nasini S, Comai S, Sut S, Dall'Acqua S, Marraudino M, Gotti S, Cifani C

Neuropharmacology2026

DOI: 10.1016/j.neuropharm.2025.110703 PMID: 41072723

Sex-dependent behavioral responses and phenotypic traits of Pcsk9 knockout mice in anxiety- and depression-like paradigms.

Nasini S, Barzon B, Tidei S, Rossi I, Lupo MG, Ferri N, Comai S

Psychoneuroendocrinology2026Senior author

DOI: 10.1016/j.psyneuen.2025.107660 PMID: 41176903

Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms.

Colognesi M, Gabbia D, Signor A, Sarill M, Centofanti L, Rinaldi A, Cascione L, Nunziata S, Banzato M, Mattarei A, Finzi G, Sonda S, Pendin D, Zanotto I, Comai S, Pasut G, Alajati A, Saponaro M, Bucciarelli L, Lunati ME, Guarato G, Goggi I, La Rosa S, Morano C, Paroni RC, Dei Cas M, Daniele G, Gentilucci M, Pappagallo M, Alimonti A, Manfredi PL, Folli F, De Martin S

Pharmacological research2026

DOI: 10.1016/j.phrs.2025.108080 PMID: 41475502

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Stefano Comai

Research

Latest papers

Latest funding

Neurophysiological and neuropharmacological effects of melatonin MT2 receptors activation in MK-801-induced schizophrenia-like dysfunctions.

Cannabidiol (CBD) modulates the serotonin-kynurenine metabolic balance in the brain of morphine-tolerant neuropathic rats.

Sex-sensitive serotonergic signaling in psychedelic pharmacology.

Up-Regulation of Anthranilic Acid Formation and Pro-Cognitive Effect of Indoleamine 2,3-Dioxygenase Inhibition.

Melatonin system integrity shapes gut-brain interaction in schizophrenia-derived microbiota transplant phenotype in mice.

Mutations in the three synapsin genes lead to profound social deficits and cortical dysfunctions.

Pharmacokinetics and safety of a modified-release psilocybin formulation: A SAD Phase I trial in normal-weight and overweight/obese participants.

Central and peripheral monoamine changes in a rat model of Gaming Disorder.

Sex-dependent behavioral responses and phenotypic traits of Pcsk9 knockout mice in anxiety- and depression-like paradigms.

Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms.

Lysergic acid diethylamide (LSD) and social behavior. A translational study.

Novel First-In-Class Melatonin MT2 Receptor Agonist for Neuropathic Pain: Investigational New Drug (IND) – Enabling Studies

Frequent collaborators

Gabriella Gobbi

Allan Fielding

Christophe Moderie

Nancy Low

Francis Bambico

Gilles Côté

Argel Aguilar-Valles

Baptiste Lacoste

Nahum Sonenberg

Gustavo Turecki

Linda Booij

Theodore Kolivakis

Terry Hébert

Robert Nadon

Clement Hamani

David Chatenet

Eileen Denovan-Wright

Vijendra Sharma

Pablo Cervantes

Jean-Claude Lacaille

Giamal Luheshi

Terence Hébert

Nicolas Flamand

Guy Rouleau

Jonathan Britt